December 8, 2016 / 1:45 PM / 8 months ago

BRIEF-AstraZeneca says FALCON trial met its primary endpoint

1 Min Read

Dec 8 (Reuters) - AstraZeneca Plc :

* AstraZeneca announces subgroup analysis from FALCON trial comparing Faslodex (fulvestrant) to Arimidex (anastrozole)

* AstraZeneca -Serious adverse events in non-visceral disease subgroup occurred in 11.6% of patients with Faslodex versus 16.8% of patients with Arimidex

* AstraZeneca Plc - safety and tolerability profile was in line with current experience with Faslodex and Arimidex

* AstraZeneca Plc - AstraZeneca is pursuing a label extension with US regulatory authorities to include falcon results in Faslodex label

* AstraZeneca Plc - FALCON trial met its primary endpoint Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below